Metrics as of 10/15/2026, 02:18 PM (Berlin time), refresh in progress.
Solvonis Therapeutics Stock
Solvonis Therapeutics plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Anthony James Tennyson
- Employees
- 6
- Market cap
- £7 M
- IPO
- 06/01/2022
- Web
- solvonis.com
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry.
Solvonis Therapeutics stock: price history
1D
-0.5%
1W
-0.5%
1M
-5.0%
6M
-59.0%
YTD
-66.3%
1Y
-72.5%
2Y
-29.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
30/06/2027 (in 256 days)
Volatility around earnings
~58% stronger price swings than usual
Ask the agents about Solvonis Therapeutics
Solvonis Therapeutics stock metrics
P/E
-1.28
P/B
1.48
EV/EBITDA
-2.04
RETURN ON EQUITY
-29.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
27.6%
FLOAT SHARES
1,877,648,499
AVG. DAILY VOLUME (30D)
25,627,019
Comparable stocks
Frequently asked questions about Solvonis Therapeutics stock
What does Solvonis Therapeutics do?
Solvonis Therapeutics plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Anthony James Tennyson, the company employs around 6 people.
The IPO was on 06/01/2022; the stock trades on LSE under the ticker SVNS.L.
When does Solvonis Therapeutics report next?
The next earnings date is 30/06/2027.
Around past earnings, price swings were roughly 58% stronger than usual.
Does Solvonis Therapeutics pay a dividend?
No, Solvonis Therapeutics currently does not pay a dividend.
Which stocks are comparable to Solvonis Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Solvonis Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Solvonis Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.